CAH's Specialty Growth Targets Reinforce High-Stakes Momentum Narrative

What happened

Cardinal Health's recent guidance, as highlighted in a Zacks article, projects specialty revenues exceeding $50 billion in FY26 with EPS growth of 23-26%, building on its expanding MSO and biopharma services ecosystem. This aligns with management's prior raises to at least $10 in non-GAAP EPS, reflecting a strategic pivot away from low-margin distribution. However, DeepValue's master report cautions that this growth is increasingly acquisition-dependent, with non-GAAP adjustments masking rising amortization costs and leverage from $5.3 billion in recent deals. The stock's 66% surge over 12 months to ~$214 has fueled crowded bullish sentiment, but valuation at 22x FY26 EPS embeds flawless execution despite risks like CVS concentration and IRA policy headwinds. While the news confirms near-term momentum, it does not address underlying earnings quality concerns or the asymmetric downside if growth normalizes.

Implication

The reaffirmation of specialty targets supports CAH's base scenario of modest EPS beats, but does not mitigate critical vulnerabilities such as high customer concentration with CVS or potential margin erosion from drug-pricing reforms. With leverage rising and GAAP earnings lagging non-GAAP figures, any integration stumble or contract loss could quickly undermine the growth story, leading to de-rating from current lofty valuations. Given the stock's momentum-driven rally and crowded ownership, a trim above $235 is prudent, while entries near $185 offer better risk-adjusted returns. Investors must closely monitor quarterly EPS tracking, GAAP vs. non-GAAP gaps, and updates on CVS contracts to avoid capital impairment. Ultimately, this news reinforces a high-stakes setup where the downside outweighs further upside without clearer FY27 visibility.

Thesis delta

The news confirms CAH's trajectory toward its FY26 specialty revenue and EPS targets, aligning with the base scenario of modest beats. However, it does not shift the core thesis, as risks around earnings quality, leverage, and external shocks remain unaddressed, keeping the 'POTENTIAL SELL' rating intact. No material change in investment outlook is warranted, emphasizing continued caution amid high expectations.